The v2.0 criteria significantly increase diagnostic sensitivity—capturing more true cases without losing specificity—by broadening the biological markers recognized by MRI.
The Boston criteria version 2.0 for cerebral amyloid angiopathy The v2
: While lobar intracerebral hemorrhage (ICH) and microbleeds remain central, cortical superficial siderosis (cSS) and convexity subarachnoid hemorrhage are now prioritized. Multiple separate foci of siderosis can now qualify a patient for a "probable CAA" diagnosis on their own. : The minimum age for applying the criteria
: The minimum age for applying the criteria has been lowered from 55 to 50 years . The "next generation" of cerebral amyloid angiopathy (CAA)
: For the first time, white matter characteristics are part of the formal criteria. A diagnosis of probable CAA can now be made with just one lobar hemorrhagic lesion if accompanied by either:
: Enlarged fluid spaces in the deep white matter.
The "next generation" of cerebral amyloid angiopathy (CAA) diagnosis is defined by the , released in late 2022 to replace the 2010 modified criteria. This update shifts the diagnostic paradigm from purely hemorrhagic markers to a more holistic "small vessel disease" profile, integrating white matter signatures. Key Evolutions in the Next Generation Criteria